Urogen Pharma (NASDAQ:URGN) Upgraded by HC Wainwright to Buy Rating

HC Wainwright upgraded shares of Urogen Pharma (NASDAQ:URGN) from a neutral rating to a buy rating in a research report released on Monday, Marketbeat.com reports. The firm currently has $50.00 target price on the stock. HC Wainwright also issued estimates for Urogen Pharma’s Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($3.10) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.26 EPS and FY2026 earnings at $0.43 EPS.

A number of other research analysts also recently commented on the company. D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of Urogen Pharma in a research note on Thursday, June 12th. Oppenheimer lowered their price objective on Urogen Pharma from $36.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday, June 3rd. The Goldman Sachs Group lowered their price objective on Urogen Pharma from $16.00 to $3.00 and set a “neutral” rating for the company in a research note on Thursday, May 22nd. LADENBURG THALM/SH SH began coverage on Urogen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. Finally, Guggenheim reissued a “buy” rating and set a $30.00 price target (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $32.86.

Urogen Pharma Price Performance

Shares of URGN opened at $14.87 on Monday. The company has a market cap of $685.66 million, a P/E ratio of -4.68 and a beta of 0.40. The stock has a fifty day moving average price of $8.79 and a 200 day moving average price of $10.10. The company has a debt-to-equity ratio of 4.77, a current ratio of 5.65 and a quick ratio of 5.47. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $18.15.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The company had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. On average, research analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Activity

In other news, insider Mark Schoenberg sold 5,162 shares of the firm’s stock in a transaction on Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the transaction, the insider now directly owns 153,378 shares of the company’s stock, valued at approximately $1,130,395.86. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in Urogen Pharma during the fourth quarter worth about $1,472,000. Lazard Asset Management LLC acquired a new position in Urogen Pharma during the fourth quarter worth about $67,000. Janus Henderson Group PLC acquired a new position in Urogen Pharma during the fourth quarter worth about $149,000. ProShare Advisors LLC acquired a new position in Urogen Pharma during the fourth quarter worth about $137,000. Finally, Bank of New York Mellon Corp grew its holdings in Urogen Pharma by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company’s stock worth $1,001,000 after acquiring an additional 6,430 shares during the period. 91.29% of the stock is owned by institutional investors and hedge funds.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.